Doppler Evaluation in RA Patients After Adalimumab.

Sponsor
Hamed Rezaei
Study ID
NCT01609205
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — BIOLOGICAL
    Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD

Study Details

The purpose is to study the relationship between RA disease activity based on Doppler quantification and the subsequent clinical response (EULAR response) to treatment with Adalimumab during 12 months. The purpose is also to compare the Doppler quantification with conventional clinical methods and semiquantitative Doppler assessment.

Key Dates

Start date
Oct 31, 2012
Status verified
Apr 2018
Primary completion
Sep 30, 2017
Completion
Sep 30, 2017

Study Design

Enrollment
60 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Adalimumab

Primary Outcome Measure

The proportion of different clinical (EULAR) response [ Time Frame: 6 months from BL ]

Related Studies